MGTA News and Press, Magenta Therapeutics Inc. From 04/14/22

– Encouraging early data and progress in MGTA-117 Phase 1/2 targeted conditioning clinical trial – – Prioritization of portfolio spending allows for extension of cash runway into Q2 2024 – Magenta Therapeutics (Nasdaq: MGTA), a clinical-st...

– First patient dosed in MGTA-117 targeted conditioning Phase 1/2 clinical trial; clinical data is expected in 2022 – – IND-enabling preclinical studies initiated for CD45 antibody-drug conjugate; dose-ranging toxicology results expected in the second half...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a Cell Therapy Panel Discussion at the 42 nd An...

Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and forme...

-- MGTA-117 Phase 1/2 clinical trial is open for enrollment for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes; clinical data expected in 2022 –- -- CD45 antibody drug conjugate is Magenta’s second conditioning program; dos...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences: 4...

-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple myeloma -- -- Phase 2 development of MGTA-145 to include new clinical trial ...

Magenta Therapeutics (NASDAQ:MGTA): Q3 GAAP EPS of -$0.30 beats by $0.03. Cash, cash equivalents and marketable securities of $192.62M. Press Release For further details see: Magenta Therapeutics EPS beats by $0.03

-- Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant engraftment using MGTA-145 plus plerixafor in patients with multiple myeloma will be presented as a poster at the 2021 American Soci...

-- Positive topline clinical data from MGTA-145 investigator-initiated Phase 2 clinical trial in multiple myeloma -- -- Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle cell disease -- --...